Review of UCN-01 development: A lesson in the importance of clinical pharmacology

Journal of Clinical Pharmacology

Volumn 45, Issue 4, 2005, Pages 394-403

  Fuse, Eiichi ^a,b   Kuwabara, Takashi ^b   Sparreboom, Alex ^a   Sausville, Edward A ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Anticancer drug; Drug development; Pharmacology; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; HUMAN IMMUNOGLOBULIN; HUMAN SERUM ALBUMIN; OROSOMUCOID; PLASMA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CLINICAL PHARMACOLOGY; COMPARTMENT MODEL; CONTINUOUS INFUSION; DOG; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SALIVA LEVEL; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; RAT; REVIEW; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; STAUROSPORINE;

EID: 16844366148     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005274549     Document Type: Review

References (29)

1. Hunter T. 1001 protein kinases redux: towards 2000. Semin Cell Biol. 1994;5:367-376.
2. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot. 1987;40:1782-1784.
3. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 1991;51:4888-4892.
4. Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of anti-tumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol. 1993;32:183-189.
5. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun. 1996;219:778-783.
6. Seynaeve CM, Stetler-Stevenson M, Sehers S, Kaur G, Sausville EA, Worland PJ. Cell cycle arrest and inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res. 1993;53:2081-2086.
7. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/ WAF1/Sdil in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 1997;57:1495-1501.
8. 1-phase accumulation. Jpn J Cancer Res. 1999;90:1364-1372.
9. Akiyama T, Shimizu M, Okabe M, Tamaoki T, Akinaga S. Differential effects of UCN-01, staurosporine and CGP41251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cell synchronized at M phase by nocodazole. Anticancer Drugs. 1999;10:67-78.
10. 1 checkpoint function as determinant of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-hydroxystaurosporine). Cancer Res. 1999;59:4406-4412.
11. Courage C, Snowden R, Gescher A. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells. Br J Cancer. 1996;74:1199-1205.
12. Sausville EA, Lush RD, Headlee D, et al. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol. 1998;42:S54-S59.
13. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol. 2001;19:2319-2333.
14. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 1997;57:4029-4035.
15. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinase 1 and 2. Cell Growth Differ. 1995;6:927-936.
16. Nieves-Neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-w, p53, MDM-2, and caspase pathways. Int J Cancer. 1999;83:396-404.
17. Bunch RT, Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res. 1996;2:791-797.
18. Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res. 1998;4:2201-2206.
19. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996;88:956-965.
20. 1-acid glycoprotein. Cancer Res. 1998;58:3248-3253.
21. Kurata N, Kuwabara T, Tanii H, et al. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer Chemother Pharmacol. 1999;44:12-18.
22. Wilkinson GR. Plasma and tissue binding considerations in drug disposition. Drug Metab Rev. 1983;14:427-465.
23. Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 1988;40:1-47.
24. 1-acid glycoprotein in humans. Cancer Res. 1999;59:1054-1060.
25. 1-acid glycoprotein. Pharm Res. 2000;17:553-564.
26. 1-acid glycoprotein on the clinical pharmacokinetics of UCN-01. Clin Cancer Res. 2004;10:6840-6846.
27. Senderowicz AM, Headlee D, Lush R, et al. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. In: Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy; June 1998; Amsterdam, The Netherlands.
28. Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res. 2005;11:664-671.
29. Haeckel R. Factors influencing the saliva/plasma ratio of drugs. Ann NY Acad Sci. 1993;694:128-142.